"We are pleased to be partnering with Soligenix on the use of their antigen to accelerate our ricin therapeutic program. There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals (SERB), for development of a novel therapeutic treatment against ricin toxin poisoning. PRINCETON, N.J., J/PRNewswire/ - Soligenix, Inc. SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen
0 Comments
Leave a Reply. |